Oculis Holding AG (OCS)
| Previous Close | 12.05 |
| Open | 12.01 |
| Bid | 11.99 x 200 |
| Ask | 12.07 x 100 |
| Day's Range | 12.00 - 12.04 |
| 52 Week Range | 9.05 - 14.50 |
| Volume | |
| Avg. Volume | 43,388 |
| Market Cap | 500.629M |
| Beta (5Y Monthly) | 0.18 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.25 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 28.44 |
GlobeNewswireOculis Announces Closing of Registered Direct Offering and Commencement of Trading on Nasdaq Iceland Main Market
Raised gross proceeds of $59 million through the issuance and sale of 5,000,000 of its ordinary shares to Icelandic institutional and existing investorsBecomes second company dual-listed on NASDAQ U.S. and NASDAQ Iceland Main Market, trading under the symbol “OCS” beginning April 23, 2024Oculis will ring the Nasdaq Iceland opening bell on April 23, 2024, at 9:30 GMTPhase 2b RELIEF trial of OCS-02 (Licaminlimab) in Dry Eye Disease (DED) remains on track to readout in Q2 2024 ZUG, Switzerland, Apr
- GlobeNewswire
Oculis Announces Completion of Oversubscribed $59 Million Registered Direct Offering and Subsequent Listing on Nasdaq Iceland Main Market
$59 million financing includes participation from new Icelandic institutional and existing investors; Extends cash runway until 2H 2026 The Central Bank of Iceland, Financial Supervision has approved Oculis’s prospectus related to the admission of its ordinary shares to trade on the Nasdaq Iceland Main Market; Oculis will announce the first day of trading with at least one day advance noticeOn-track to report topline data from OCS-02 (licaminlimab) Phase 2b RELIEF trial in Dry Eye Disease (DED)
- GlobeNewswire
Oculis Strengthens its Executive Leadership Team with the Appointment of Snehal Shah, Pharm.D. as President of Research & Development
Following significant strides made in advancing its late-stage pipeline with dual positive readouts in 2023 and a few more anticipated this year, Oculis further expands its executive leadership team with the appointment of industry veteran as President of Research & DevelopmentDr. Shah’s joins Oculis from Iveric Bio with extensive experience in drug development, regulatory affairs and ophthalmology, with over a dozen successful market approvals, which will be key as Oculis initiates preparations
